01 Industry overview
The AI regulatory writing industry at a glance
The AI regulatory writing market is estimated at $1.9 billion in 2026, with adoption expanding as life-sciences companies apply generative AI to submissions, regulatory intelligence, and compliance workflows.
- $1.9B[8]
- AI regulatory affairs market, 2026
- 18.65%[8]
- Forecast CAGR, 2026–2031
- 33%
- AI use in regulatory affairs, 2026
- 500+[9]
- FDA submissions with AI components
- Market size
- The global AI in regulatory affairs market is projected to reach $1.9 billion in 2026. A closely related AI medical-writing market was estimated at $1.06 billion in 2025, indicating that regulatory writing is developing within a broader medical and regulatory content market.[8][10]
- Forecast & CAGR
- AI in regulatory affairs is forecast to grow at a compound annual growth rate of 18.65% from 2026 to 2031, reaching $4.47 billion by 2031. The wider global regulatory affairs market is forecast to grow at 8.8% from 2025 to 2030.[8][1]
- Market share & regions
- Asia Pacific accounted for 38.0% of the global regulatory affairs market in 2024, while North America represented 41.5% of the broader regulatory affairs market in 2025 in another market estimate. These figures describe the surrounding regulatory-affairs market rather than AI regulatory writing alone.[1][4]
- Segmentation
- The market is segmented around regulatory-affairs services and technology applications, including regulatory consulting, legal representation, regulatory intelligence, submission preparation, and regulatory information-management platforms. AI use cases increasingly include document drafting, content review, information retrieval, and submission workflow automation.[1][11]
- Key players & concentration
- The competitive landscape combines established life-sciences services and regulatory-information providers with specialist AI and generative-AI vendors. Public sources reviewed do not provide a reliable market-share or concentration ratio for AI regulatory writing specifically.[11][12]
- Trends, drivers & challenges
- The main drivers are pressure to reduce manual work, accelerate time to market, and improve consistency in regulatory submissions. Adoption remains constrained by validation, data governance, confidentiality, hallucination risk, and the need for human review; KPMG reports that 33% of surveyed life-sciences organizations use AI in regulatory affairs and government relations today.[11][12]
- Consumer behavior & competition
- The primary buyers are pharmaceutical, biotechnology, medical-device, and contract-research organizations rather than individual consumers. In a 2025 Salesforce survey, 64% of life-sciences regulatory and compliance leaders said they were very excited about using AI in everyday work, while competition is centered on secure, auditable, domain-specific platforms.[13][11]
- Regulation
- The U.S. FDA said in January 2025 that it had experience reviewing more than 500 drug and biological-product submissions containing AI components since 2016. FDA guidance and draft frameworks emphasize credibility, risk-based validation, lifecycle controls, and appropriate documentation of AI use in submissions.[9]
- Latest news
- In 2026, KPMG reported that 33% of surveyed life-sciences organizations were already using AI in regulatory affairs and government relations, with 38% expecting use within two years. FDA materials published in 2025 also continued to formalize expectations for AI-enabled products and AI-supported regulatory decision-making.[9]
02 Ranking
Top 10 Companies in the AI Regulatory Writing Industry
The leading companies in the AI regulatory writing industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Indegene stands out for AI-enabled regulatory writing and submissions workflows because it runs authoring, labeling and submission workflows, while Veristat focuses on essential regulatory documentation in clinical-trial medical writing since it provides medical writing for clinical trials and essential regulatory documentation.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in regulatory and medical writing
Indegene
IN
Ranked #1 · 9.3 · Regulatory and medical writing
Why we picked it: It runs AI-enabled regulatory writing, authoring, labeling, and submission workflows, with an operating margin of 16.1%.
#2 overall
Veristat
US
Ranked #2 · 9.1 · Regulatory and medical writing
Why we picked it: It provides medical writing services for clinical trials and essential regulatory documentation.
#3 overall
IQVIA
US
Ranked #3 · 9.0 · Regulatory and medical writing
Why we picked it: It provides AI-supported regulatory language, medical writing, and submission workflows with an operating margin of 13.4%.
Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Indegene Regulatory and medical writing · IN | 9.3 | 8.9 | 9.9 | 9.9 | 8.9 | |
Company snapshot · Indegene · Data as of November 20, 2026 Indegene runs AI-enabled regulatory writing, authoring, labeling and submission workflows.[14]
| |||||||
| 2 | Veristat Regulatory and medical writing · US | 9.1 | 8.8 | 8.9 | 9.8 | 9.9 | |
Company snapshot · Veristat · Data as of November 20, 2026 Veristat provides medical writing for clinical trials and essential regulatory documentation.[15]
| |||||||
| 3 | IQVIA Regulatory and medical writing · US | 9.0 | 8.8 | 8.0 | 8.9 | 9.9 | |
Company snapshot · IQVIA · Data as of November 20, 2026 IQVIA provides AI-supported regulatory language, medical writing and submission workflows.[12]
| |||||||
| 4 | AlphaLife Sciences Regulatory and medical writing | 8.6 | 7.8 | 8.9 | 9.3 | 8.9 | |
Company snapshot · AlphaLife Sciences · Data as of November 20, 2026 AlphaLife Sciences offers AuroraPrime for AI-assisted clinical and regulatory medical writing.[16]
| |||||||
| 5 | Acriba Regulatory and medical writing | 8.2 | 7.0 | 8.3 | 9.3 | 8.9 | |
Company snapshot · Acriba · Data as of November 20, 2026 Acriba combines expert regulatory writing with section-aware AI and sentence-level source traceability.[17]
| |||||||
| 6 | Sanai AI regulatory documentation platform · US | 8.2 | 7.0 | 8.3 | 8.9 | 8.9 | |
Company snapshot · Sanai · Data as of November 20, 2026 Sanai drafts cited regulatory filings, CSRs, protocols and SOPs for life-sciences teams.[18]
| |||||||
| 7 | ICON AI-enabled medical and regulatory writing CRO · IE | 8.2 | 8.8 | 7.0 | 7.0 | 8.9 | |
Company snapshot · ICON · Data as of November 20, 2026 ICON uses secure AI for CSR, patient narrative and plain-language-summary generation.[19]
| |||||||
| 8 | Asthra AI AI regulatory writing software | 8.0 | 7.0 | 7.8 | 8.9 | 8.9 | |
Company snapshot · Asthra AI · Data as of November 20, 2026 Asthra drafts source-grounded, cited regulatory documents inside Microsoft Word.[6]
| |||||||
| 9 | Yseop AI regulatory and medical writing software · US | 8.0 | 9.9 | 7.8 | 7.0 | 7.0 | |
Company snapshot · Yseop · Data as of November 20, 2026 Yseop provides generative AI for regulatory writing and scientific content automation.[20]
| |||||||
| 10 | QInscribe AI-assisted regulatory writing CRO · GB | 7.9 | 7.0 | 7.8 | 8.9 | 8.0 | |
Company snapshot · QInscribe · Data as of November 20, 2026 QInscribe uses AI-assisted workflows and expert review to deliver regulatory documents.[21]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 20). Top 10 companies in the AI regulatory writing industry. In AI Regulatory Writing Industry Statistics. Gitnux. https://gitnux.org/ai-regulatory-writing-industry-statistics/#top-companies
03 Trends & forecasts
Top 10 AI Regulatory Writing Industry Trends & Forecasts 2027
What is changing in the AI regulatory writing industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Document generation becomes the lead use case
High confidenceIn Salesforce’s 2025 life-sciences survey, document generation, consent and contract management ranked among the most valuable AI use cases, alongside regulatory reporting and streamlined compliance. The findings support demand for tools that produce first drafts and transform existing regulated content.[13]
Forecast 2027: In 2027, document generation will remain the largest practical application for AI regulatory writing. Vendors will increasingly package drafting with source linking, controlled terminology, review workflows and change tracking.
02Regulatory intelligence automation accelerates
High confidenceCapgemini reported that 40% of pharmaceutical and biotechnology organizations were piloting AI for regulatory intelligence and strategy in research conducted in August–September 2025. This places regulatory intelligence among the most active early-stage AI applications.[22]
Forecast 2027: By 2027, regulatory-intelligence systems will move from pilots toward production use for monitoring guidance, comparing jurisdictions and identifying submission impacts. Demand will favor systems that provide citations and preserve an auditable reasoning trail.
03Human review remains mandatory
High confidenceFDA’s proposed framework for AI models used in drug and biological-product submissions emphasizes risk-based credibility assessment and appropriate safeguards. Salesforce also identified compliance risk and lack of trust in underlying data as major factors limiting enthusiasm for workplace AI.[9][13]
Forecast 2027: In 2027, AI regulatory-writing products will generally be sold as human-in-the-loop systems rather than autonomous authors. Review checkpoints, approval records and accountable subject-matter experts will remain standard requirements for high-impact documents.
04Evidence traceability becomes a differentiator
High confidenceICH E6(R3), effective for its main principles and Annex 1 from July 23, 2025, emphasizes data integrity, traceability, security and fit-for-purpose computerized systems. These requirements increase the value of AI tools that connect generated text to controlled source evidence.[23][24]
Forecast 2027: By 2027, citation-level provenance will be a core purchasing criterion for regulatory-writing platforms. Products without reliable links to source documents, version history and reviewer actions will struggle in validated environments.
05Validation services grow alongside software
High confidenceFDA’s 2025 AI credibility framework calls for sponsors to assess the credibility of AI models for a specific context of use and determine the credibility activities needed to support the output. Life-sciences surveys also identify risk management, compliance and implementation capability as material adoption barriers.[9]
Forecast 2027: In 2027, implementation revenue will expand beyond licenses into validation plans, model monitoring, qualification testing and operating procedures. Specialist consultancies and contract research organizations will use validation support to differentiate from generic AI vendors.
06Agentic workflows enter controlled production
Medium confidenceSalesforce reported that 94% of life-sciences leaders considered agents critical to keeping up with changing regulations. The same survey identified regulatory reporting and streamlined compliance as leading valuable AI use cases.[13]
Forecast 2027: In 2027, agents will increasingly handle bounded tasks such as assembling source packets, routing review comments, checking document completeness and monitoring regulatory changes. Fully autonomous drafting or filing will remain uncommon because of validation and accountability requirements.
07Global content localization scales faster
Medium confidenceICH E6(R3) provides a harmonized framework intended to support mutual acceptance of clinical-trial results across ICH regions, while Deloitte identifies global reach and collaboration as expected benefits of AI-enabled medical and regulatory writing. These conditions support multilingual reuse of controlled regulatory content.[23][25]
Forecast 2027: By 2027, AI regulatory-writing platforms will expand multilingual drafting, terminology management and jurisdiction-specific adaptation. The strongest demand will come from sponsors preparing coordinated submissions across the United States, Europe and Asia.
08Regulatory writing shifts toward platforms
High confidenceIndustry research describes AI use across submission automation, regulatory intelligence, review and compliance support rather than in isolated writing tools. Deloitte also describes integrating generative AI with existing technologies and regulatory authoring workflows.[22][25]
Forecast 2027: In 2027, buyers will favor integrated platforms connected to regulatory information-management, document-management and quality systems. Standalone text-generation tools will face pressure to add workflow, permissions, audit trails and structured submission support.
09Regulatory AI workloads broaden beyond drugs
Medium confidenceFDA’s Center for Biologics Evaluation and Research describes AI/ML activity spanning biological products and pharmaceutical manufacturing, while RAPS identifies use cases including medical-device technical files, CMC modules and clinical evaluation reports. This shows demand extending across product classes and document types.[9][26]
Forecast 2027: By 2027, medical devices, biologics and manufacturing documentation will represent a larger share of AI regulatory-writing activity. Vendors with cross-product templates and configurable controls will have an advantage over tools designed only for drug submissions.
10EU compliance work creates 2027 demand
High confidenceThe EU AI Act’s current text sets compliance dates of August 2, 2027 for general-purpose AI models placed on the market before August 2, 2025, and December 2, 2027 for certain high-risk AI-system obligations under the amended timetable. These dates create a defined compliance milestone for vendors and deployers using AI in regulated workflows.[27]
Forecast 2027: During 2027, EU-facing buyers will increase spending on AI inventories, technical documentation, transparency records and governance evidence. Regulatory-writing suppliers will add features that help customers document model use and demonstrate compliance across jurisdictions.
04 Statistics
Market Intelligence
Market-intelligence figures place regulatory writing inside broader AI-in-medical-writing categories, with the AI-in-medical-writing market projected to reach $1.99 billion by 2030.
Market size and revenue in the AI regulatory writing industry
- $1.00 billion was the global AI-in-medical-writing market size in 2025, covering clinical, scientific and other writing types and including regulatory-document use cases, according to Grand View Research.[1]
- $1.16 billion was the global AI-in-medical-writing market size in 2025, with regulatory writing identified as a distinct application segment, according to Fortune Business Insights.[2]
- $1.05 billion was the global AI-in-medical-writing market revenue in 2025, including regulatory documentation, clinical writing, scientific writing and related applications, according to The Business Research Company.[3]
Growth forecasts for the AI regulatory writing industry
- The global AI-in-medical-writing market is projected to reach $3.5 billion by 2033, with a 16.4% CAGR from 2026 to 2033; regulatory documents are included within the study scope.[1]
- The global AI-in-medical-writing market is projected to reach $1.99 billion by 2030, growing at a 13.4% CAGR from 2026 to 2030; the market includes regulatory documentation and regulatory submission documents.[3]
- The global AI-in-medical-writing market is projected to reach $9.04 billion by 2034, growing at a 24.99% CAGR from 2026 to 2034; regulatory writing is a named application segment.[2]
- The global AI-in-medical-writing market is projected to reach $973.1 million by 2035, growing at a 19.0% CAGR from 2026 to 2035; regulatory submission documents are a named document type.[4]
Regional breakdown of the AI regulatory writing industry
- North America held 36.5% of global AI-in-medical-writing revenue in 2025; the study includes regulatory-document production and reports the regional share for the broader category.[1]
- The United States generated $249.0 million of AI-in-medical-writing revenue in 2025; regulatory writing is included within the broader market definition.[1]
- North America’s AI-in-medical-writing market was valued at $0.50 billion in 2025; regulatory writing is a named application within the broader market study.[2]
05 Statistics
Pricing & Packaging
Published pricing points concentrate around software plans and per-deliverable drafts, including $99 per month for an AI regulatory-intelligence writing assistant.
Price levels in the AI regulatory writing industry
- $99 per month is the published individual-plan price for Gulfstream Intelligence’s AI regulatory-intelligence platform, which includes a Writing Assistant; observed in November 2026 for the United States market.[5]
- $1,999 per clinical study report or trial-protocol first draft is Asthra AI’s published self-serve price; observed in November 2026 for its AI regulatory-writing software in life sciences.[6]
- $4,990 per year is CMCfy’s published Professional-plan price for one user, including 150 AI writing runs per month; observed in November 2026 for its US/EU regulatory-writing software.[7]
Key questions about the AI regulatory writing industry
What is the 2026 market size for AI regulatory writing?
How fast is AI in regulatory affairs expected to grow?
Which companies lead the AI regulatory writing industry?
What technology shifts show up in 2026 usage?
How is the market structured between services and technology?
How many FDA submissions include AI components?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 20). AI Regulatory Writing Industry Statistics. Gitnux. https://gitnux.org/ai-regulatory-writing-industry-statistics
Samuel Norberg. "AI Regulatory Writing Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/ai-regulatory-writing-industry-statistics.
Samuel Norberg. 2026. "AI Regulatory Writing Industry Statistics." Gitnux. https://gitnux.org/ai-regulatory-writing-industry-statistics.
Sources & references
27 sources cited across this report
grandviewresearch.com
fortunebusinessinsights.com
thebusinessresearchcompany.com
emergenresearch.com
- gulfstreamintelligence.com
- asthra-writer.ai
- cmcfy.com
mordorintelligence.com
fda.gov
medidata.com
everestgrp.com
iqvia.com
salesforce.com
ir.indegene.com
veristat.com
- alphalifesci.com
- acriba.co
- sanai.ai
iconplc.com
yseop.com
- qinscribe.com
capgemini.com
ema.europa.eu
database.ich.org
deloitte.com
raps.org
eur-lex.europa.eu
